Business Context and Reporting Period
Company: Varex Imaging Corp (VREX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended June 28, 2024 (Q3 Fiscal 2024) and Nine Months ended June 28, 2024.
Business Overview: Varex designs, manufactures, and sells X-ray imaging components for medical (diagnostic, therapy, dental) and industrial (security, inspection) markets. The company operates two segments: Medical and Industrial.
Key Financial Metrics
| Metric (in millions) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenues, Net | $209.1 | $232.2 | $605.3 | $666.0 |
| Gross Profit | $66.9 | $76.3 | $189.8 | $212.3 |
| Gross Margin | 32.0% | 32.9% | 31.4% | 31.9% |
| Operating Income | $9.3 | $24.2 | $21.2 | $52.8 |
| Net Income (Varex) | $1.4 | $9.1 | $2.3 | $16.3 |
| Diluted EPS | $0.03 | $0.21 | $0.06 | $0.40 |
| Cash & Equivalents | $156.4 | $152.6 | $156.4 | $152.6 |
| Total Debt (Net) | $443.1 | $442.6 | $443.1 | $442.6 |
| Operating Cash Flow (9M) | $21.4 | $61.3 | $21.4 | $61.3 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 9.9% in Q3 and 9.1% for the nine-month period compared to the prior year.
- Medical Segment: Revenue dropped 15.3% in Q3 (down $26.8M) and 14.2% for the nine months. Declines were driven by reduced sales in dental, mammography, oncology, and fluoroscopy, partially offset by CT growth. Management cites the Chinese government's anti-corruption campaign and cautious customer purchasing as primary headwinds.
- Industrial Segment: Revenue increased 6.5% in Q3 (up $3.7M) and 7.4% for the nine months, driven by security inspection products and X-ray tubes.
- Margin Compression: Gross margin declined to 32.0% in Q3 from 32.9% in Q3 2023. The Medical segment margin slipped slightly to 31.1%, while the Industrial segment margin fell to 34.2% from 38.0% due to unfavorable product mix shifts.
- Operating Expenses: Total operating expenses increased 10.6% in Q3. Selling, General, and Administrative (SG&A) expenses rose 10.9% due to increased fixed cost commitments to a supplier (dpiX), litigation costs, and environmental remediation costs. R&D expenses increased 10.0%.
- Profitability: Net income attributable to Varex plummeted 84.6% in Q3 to $1.4M from $9.1M in the prior year, primarily due to lower revenues and higher operating expenses.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management remains cautious regarding the general economic environment. They expect the negative impact of the Chinese anti-corruption campaign and cautious purchasing behaviors to continue through the remainder of fiscal year 2024.
- Debt Refinancing: The company has $200.0M in Convertible Senior Unsecured Notes maturing in June 2025. Management anticipates refinancing these notes using a combination of borrowings under their new Revolving Credit Facility and cash.
- New Credit Facilities: In March 2024, the company entered a $155.0M Senior Secured Revolving Credit Facility (undrawn as of June 28, 2024). In April 2024, a $20.0M Equipment Credit Facility was established (also undrawn).
- Unusual Items:
- Business Combination: In Q1 2024, Varex acquired a controlling interest in MeVis Breastcare, recognizing a $1.2M gain on bargain purchase and a $0.9M gain on remeasurement of the previous equity interest.
- Debt Costs: Termination of the previous Asset-Based Loan (ABL) facility resulted in the recognition of $0.6M in unamortized issuance costs.
- Risks:
- Customer Concentration: One customer (Canon Medical Systems) accounted for 18.0% of Q3 revenue. The top 10 customers accounted for 54% of revenue.
- Supply Chain: Reliance on limited suppliers for key components (e.g., transistor arrays) and geopolitical tensions (China/Taiwan, Russia/Ukraine) pose risks to manufacturing and delivery.
- Legal Proceedings: Ongoing disputes regarding joint ventures (VEC Imaging in Germany and Varex Imaging Arabia) could divert management attention and increase costs.
Investor Verification Checklist
- Refinancing Plan: Verify the company's ability to refinance the $200M Convertible Notes due June 2025, given the current undrawn status of the new credit facilities and the significant drop in operating cash flow.
- China Exposure: Assess the duration and severity of the Chinese anti-corruption campaign's impact on the Medical segment, which constitutes the majority of revenue.
- Supplier Commitments: Review the $12.4M annual fixed cost commitment to dpiX (a joint venture supplier) and its impact on margins if sales volumes do not recover.
- Legal Contingencies: Monitor the status of the VEC Imaging and Saudi Arabia joint venture disputes for potential financial or operational disruptions.
- Inventory Levels: Note that inventories increased to $281.7M (from $277.5M at year-end) while revenue declined, potentially indicating slower turnover or build-up for future demand.